Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORDETTE-21 vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to prevent sperm penetration, and alters endometrial lining to reduce implantation likelihood.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Prevention of pregnancy in women who elect to use oral contraceptives
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Ethinylestradiol: 13 ± 7 hours (terminal), clinically relevant for once-daily dosing; Levonorgestrel: 24 ± 6 hours (terminal), supporting steady-state after ~5 days
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Ethinyl estradiol and levonorgestrel are metabolized primarily by CYP3A4. Ethinyl estradiol undergoes phase II conjugation (glucuronidation/sulfation). Levonorgestrel is reduced and conjugated.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Renal: ~50% (as glucuronide and sulfate conjugates); Fecal: ~40% (enterohepatic recirculation); Biliary: <10%
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Ethinylestradiol: 98% bound to albumin; Levonorgestrel: 50% to SHBG, 50% to albumin
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
Ethinylestradiol: 2.5-10 L/kg (extensive tissue distribution); Levonorgestrel: 1.5-4 L/kg (distributes to breast and uterine tissues)
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Oral: Ethinylestradiol 40-60% (first-pass metabolism); Levonorgestrel 90-100% (minimal first-pass)
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use is not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in acute hepatic disease, hepatic adenomas, or severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment available.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Not indicated for use before menarche. For postmenarchal adolescents, same adult dosing (one tablet daily for 21 days) is used based on chronological age and physical development.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly patients if renal and hepatic function are normal, but alternative contraception should be considered due to increased risk of thromboembolism.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
Cigarette smoking increases the risk of serious cardiovascular adverse events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should use other contraception.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI). Risk increased with smoking, hypertension, hyperlipidemia, diabetes, obesity, and age >35. Discontinue if jaundice, visual disturbances, or migraine develops. Monitor for hypertension, glucose intolerance, and depression. May affect lipid metabolism. Use with caution in women with a history of depression, migraine, or gallbladder disease.
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Known or suspected pregnancy; current or history of thromboembolic disorders (e.g., DVT, PE, stroke, MI); current or history of cerebrovascular or coronary artery disease; known or suspected breast carcinoma; active liver disease (e.g., hepatitis, cirrhosis); undiagnosed abnormal uterine bleeding; heavy smoking (>15 cigarettes/day) and age ≥35; hypersensitivity to any component.
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
No known significant food interactions. Grapefruit juice may slightly increase estrogen levels but not considered clinically relevant. Taking with food may reduce nausea.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
Trimester 1: No increased risk of major birth defects. Trimester 2-3: Possible risk of fetal harm (e.g., estrogenic effects on genital development) when used inadvertently.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Passes into breast milk. M/P ratio not determined. Use not recommended during breastfeeding due to potential estrogenic effects on nursing infant.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
Contraindicated in pregnancy; no dose adjustments recommended as drug should be discontinued if pregnancy occurs.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Nordette-21 (ethinyl estradiol/levonorgestrel) is a monophasic oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting or severe diarrhea occurs. CYP3A4 inducers (e.g., rifampin) may reduce efficacy. Do not prescribe with certain anticonvulsants or St. John's wort.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Take one tablet daily at the same time each day for 21 days, then 7 days off.,Use backup contraception (e.g., condoms) for the first 7 days of initial use.,If you miss a pill, follow the package instructions; use backup if needed.,Seek immediate medical attention for signs of blood clots, stroke, or liver problems.,Hormonal contraceptives do not protect against STDs, including HIV.,Notify your doctor if you become pregnant or plan to become pregnant.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORDETTE-21 vs ESTROSTEP 21, answered by our medical review team.
NORDETTE-21 is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to prevent sperm penetration, and alters endometrial lining to reduce implantation likelihood.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORDETTE-21 and ESTROSTEP 21 depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORDETTE-21 is: One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORDETTE-21 and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORDETTE-21 is classified as Category C. Trimester 1: No increased risk of major birth defects. Trimester 2-3: Possible risk of fetal harm (e.g., estrogenic effects on genital development) when used inadvertently.. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.